386 related articles for article (PubMed ID: 25622899)
1. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
2. A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas.
Imperiale A; Moussallieh FM; Sebag F; Brunaud L; Barlier A; Elbayed K; Bachellier P; Goichot B; Pacak K; Namer IJ; Taïeb D
PLoS One; 2013; 8(11):e80539. PubMed ID: 24312232
[TBL] [Abstract][Full Text] [Related]
3. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.
Rao JU; Engelke UF; Rodenburg RJ; Wevers RA; Pacak K; Eisenhofer G; Qin N; Kusters B; Goudswaard AG; Lenders JW; Hermus AR; Mensenkamp AR; Kunst HP; Sweep FC; Timmers HJ
Clin Cancer Res; 2013 Jul; 19(14):3787-95. PubMed ID: 23723300
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
[TBL] [Abstract][Full Text] [Related]
6. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
Vicha A; Musil Z; Pacak K
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
[TBL] [Abstract][Full Text] [Related]
7. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
Shankavaram U; Fliedner SM; Elkahloun AG; Barb JJ; Munson PJ; Huynh TT; Matro JC; Turkova H; Linehan WM; Timmers HJ; Tischler AS; Powers JF; de Krijger R; Baysal BE; Takacova M; Pastorekova S; Gius D; Lehnert H; Camphausen K; Pacak K
Neoplasia; 2013 Apr; 15(4):435-47. PubMed ID: 23555188
[TBL] [Abstract][Full Text] [Related]
8. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
9. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
[TBL] [Abstract][Full Text] [Related]
11. Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics.
Rao JU; Engelke UF; Sweep FC; Pacak K; Kusters B; Goudswaard AG; Hermus AR; Mensenkamp AR; Eisenhofer G; Qin N; Richter S; Kunst HP; Timmers HJ; Wevers RA
J Clin Endocrinol Metab; 2015 Feb; 100(2):E214-22. PubMed ID: 25459911
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
13. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.
Lendvai N; Pawlosky R; Bullova P; Eisenhofer G; Patocs A; Veech RL; Pacak K
Endocrinology; 2014 Jan; 155(1):27-32. PubMed ID: 24189137
[TBL] [Abstract][Full Text] [Related]
14. GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES.
Michałowska I; Ćwikła JB; Michalski W; Wyrwicz LS; Prejbisz A; Szperl M; Nieć D; Neumann HP; Januszewicz A; Pęczkowska M
Endocr Pract; 2017 Mar; 23(3):342-352. PubMed ID: 27967220
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.
Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA
J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889
[TBL] [Abstract][Full Text] [Related]
16. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic Urine Profile: Searching for New Biomarkers of SDHx-Associated Pheochromocytomas and Paragangliomas.
Martins RG; Gonçalves LG; Cunha N; Bugalho MJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5467-5477. PubMed ID: 31504671
[TBL] [Abstract][Full Text] [Related]
18. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
Vicha A; Taieb D; Pacak K
Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
[TBL] [Abstract][Full Text] [Related]
19. Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline
Santi R; Rapizzi E; Canu L; Ercolino T; Baroni G; Fucci R; Costa G; Mannelli M; Nesi G
Anticancer Res; 2017 Feb; 37(2):805-812. PubMed ID: 28179334
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update.
Persu A; Lannoy N; Maiter D; Mendola A; Montigny P; Oriot P; Vinck W; Garin P; Hamoir M; Vikkula M
Horm Metab Res; 2012 May; 44(5):349-53. PubMed ID: 22566194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]